Corindus Vascular Robotics Inc (A:CVRS)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
See Regulatory Filings on SEC
Company Contact
Address: 309 Waverley Oaks Rd Ste 105
WALTHAM MA 02452-8451
Tel: 1-508-6533335
IR: See website
Key People
Business Overview
Corindus Vascular Robotics, Inc. is engaged in robotic-assisted vascular interventions. The Company's CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System it brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. It operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit.
Financial Overview
For the three months ended 31 March 2019, Corindus Vascular Robotics Inc revenues increased from $1.5M to $3M. Net loss applicable to common stockholders decreased 32% to $10.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling, general and administrative - Ba decrease of 8% to $6.3M (expense).
Employees: 90 as of Mar 8, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $564.49M as of Mar 31, 2019
Annual revenue (TTM): $12.33M as of Mar 31, 2019
EBITDA (TTM): -$32.45M as of Mar 31, 2019
Net annual income (TTM): -$37.66M as of Mar 31, 2019
Free cash flow (TTM): -$31.48M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 206,700,168 as of May 1, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization